Exhibit 5.3
| | | | |
| | A&L Goodbody Solicitors | | Dublin |
| International Financial Services Centre | | Belfast |
| 25-28 North Wall Quay, Dublin 1 | | London |
| D01 H104 | | New York |
| T +353 1 649 2000 | | San Francisco |
| Dx: 29 Dublin | www.algoodbody.com | | Palo Alto |
| | |
Date | | 5 October 2020 |
Our Ref | | 01416740 |
Iterum Therapeutics International Limited
Block 2 Floor 3, Harcourt Centre
Harcourt Street
Dublin 2
Ireland
Iterum Therapeutics International Limited
6.50% Exchangeable Senior Subordinated Notes due 2025 and Royalty-Linked Subordinated Notes of Iterum Therapeutics Bermuda Limited, each guaranteed by, amongst others, Iterum Therapeutics International Limited
Dear Sirs
We are acting as Irish counsel to Iterum Therapeutics International Limited, a private limited company incorporated under the laws of Ireland (registered number 564304) (the Company) in connection with the filing of a registration statement (including any amendments thereto, the Registration Statement) on Form S-1 by the Company, the Company’s parent, Iterum Therapeutics plc, a public limited company incorporated under the laws of Ireland (registered number 563531) (ITP), Iterum Therapeutics Bermuda Limited, a company formed under the laws of Bermuda (the Issuer), Iterum Therapeutics US Limited, a company formed under the laws of Delaware (ITUL), and Iterum Therapeutics US Holding Limited, a company formed under the laws of Delaware (ITUH), with the United States Securities and Exchange Commission (the SEC) under the Securities Act of 1933, as amended (the Securities Act).
Pursuant to the Registration Statement, we understand that the Issuer and ITP will register for the resale by the selling securityholders listed in the Registration Statement:
| (i) | $51,588,000 principal amount of 6.500% Exchangeable Senior Subordinated Notes due 2025 (the Exchangeable Notes), issued by the Issuer, which Exchangeable Notes in certain circumstances and subject to their terms may be exchanged and if exchanged may be settled, including payment of interest thereon, in cash, ordinary shares of ITP, nominal value $0.01 per share (the Exchange Shares), or a combination of cash and Exchange Shares; |
| (ii) | $103,176 principal amount of Limited Recourse Royalty-Linked Subordinated Notes (the Royalty-Linked Notes, and together with the Exchangeable Notes, the Notes) issued by the Issuer; and |
| (iii) | the Exchange Shares, if any, |
PM Law • CE Gill • JG Grennan • J Coman • PD White • VJ Power • LA Kennedy • SM Doggett • B McDermott • C Duffy • PV Maher • S O’Riordan • MP McKenna • KA Feeney • M Sherlock EP Conlon • E MacNeill • KP Allen • EA Roberts • C Rogers • G O’Toole • JN Kelly • N O’Sullivan • MJ Ward • AC Burke • D Widger • C Christle • S O’Croinin • JW Yarr • DR Baxter A McCarthy • JF Whelan • JB Somerville • MF Barr • AM Curran • A Roberts • M Dale • RM Moore • D Main • J Cahir • M Traynor • PM Murray • P Walker • K Furlong • PT Fahy • D Inverarity M Coghlan • DR Francis • A Casey • B Hosty • M O’Brien • L Mulleady • K Ryan • E Hurley • G Stanley • D Dagostino • R Grey • R Lyons • J Sheehy • C Morrissey C Carroll • SE Carson • P Diggin • J Williams • A O’Beirne • MD Cole • G Conheady • J Dallas • SM Lynch • M McElhinney • C Owens • AD Ion • K O’Connor • JH Milne • T Casey • M Doyle CJ Comerford • R Marron • D Berkery • K O’Shaughnessy • S O’Connor • SE Murphy • D Nangle • L Butler • A Lawler • C Ó Conluain • N McMahon • HP Brandt • A Sheridan
Consultants: SW Haughey • Professor JCW Wylie • AF Browne • MA Greene • AV Fanagan